COMP <GO>
MXCT vs ABBV // PIOTROSKI F-SCORE QUALITY
MaxCyte Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MXCT 2
— ABBV 9
▲ PIOTROSKI F-SCORE QUALITY LEADER: ABBV
LAST: $1.73 (+1.17%) • MKT CAP: $178.5M
piotroski-score
3/9
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MXCT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MXCT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 70.20% | +25.80 | MXCT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.10% | 29.00% | -56.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -20.26% | 3.47% | -23.73 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -5.70% | 8.60% | -14.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.52 | 5.33 | -3.81 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.4 | 65.1 | +0.26 | MXCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $178.5M | $513.86B | -$513.68B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MXCT REV | ABBV REV | MXCT GROSS % | ABBV GROSS % | MXCT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.0M | $61.16B | 98.0% | 70.2% | -$36.2M | $17.82B |
| FY 2024 | $22.2M | $56.33B | 98.0% | 70.0% | -$29.3M | $17.83B |
| FY 2023 | $19.5M | $54.32B | — | — | -$21.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MXCT // BETA —
ABBV // BETA 1.15